Literature DB >> 11862087

N-acetylcysteine in chronic blepharitis.

Elvan Yalçin1, Feyza Altin, Feriha Cinhüseyinoglue, M Okan Arslan.   

Abstract

PURPOSE: To investigate the effects of N-acetylcysteine (NAC) in chronic posterior blepharitis.
METHODS: This was a prospective randomized, controlled study that included 79 eyes of 40 patients with chronic posterior blepharitis. Routine ophthalmologic examination, Schirmer-1 test, fluorescein break-up time (FBUT), and mucous fern tests were carried out during the first visit of all patients. A topical steroid, topical antibiotic, and artificial tears were started in 36 eyes of 18 patients. The therapy group (43 eyes of 22 patients) was administered three daily doses of 100 mg oral NAC. All patients were examined weekly for 1 to 4 months (average, 24 +/- 0.7). A Schirmer-1 test and FBUT were administered at every visit, but mucous fern tests were administered every two weeks. The results of the first and last Schirmer-1 tests, FBUT, and mucous fern test were compared between the therapy and control groups. Student's t and Mann-Whitney U tests were used for statistical analysis.
RESULTS: FBUT was significantly increased (p < 0.0001), and the mucous fern pattern was also significantly improved (p = 0.0096) in the therapy group.
CONCLUSION: NAC is thought to increase FBUT and improve mucous fern pattern by blocking lipid peroxidation in chronic blepharitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11862087     DOI: 10.1097/00003226-200203000-00007

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  9 in total

Review 1.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  N-acetylcysteine -- passe-partout or much ado about nothing?

Authors:  Mirja-Liisa Aitio
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 3.  The international workshop on meibomian gland dysfunction: report of the clinical trials subcommittee.

Authors:  Penny A Asbell; Fiona J Stapleton; Kerstin Wickström; Esen K Akpek; Pasquale Aragona; Reza Dana; Michael A Lemp; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 4.  The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction.

Authors:  Gerd Geerling; Joseph Tauber; Christophe Baudouin; Eiki Goto; Yukihiro Matsumoto; Terrence O'Brien; Maurizio Rolando; Kazuo Tsubota; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-30       Impact factor: 4.799

Review 5.  N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review.

Authors:  Mohamed Farouk Chughlay; Nicole Kramer; C Wendy Spearman; Mahmoud Werfalli; Karen Cohen
Journal:  Br J Clin Pharmacol       Date:  2016-03-02       Impact factor: 4.335

6.  NQO1 downregulation potentiates menadione-induced endothelial-mesenchymal transition during rosette formation in Fuchs endothelial corneal dystrophy.

Authors:  Kishore Reddy Katikireddy; Tomas L White; Taiga Miyajima; Shivakumar Vasanth; Duna Raoof; Yuming Chen; Marianne O Price; Francis W Price; Ula V Jurkunas
Journal:  Free Radic Biol Med       Date:  2017-12-30       Impact factor: 7.376

7.  N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review protocol.

Authors:  Mohamed Farouk Chughlay; Nicole Kramer; Mahmoud Werfalli; Wendy Spearman; Mark Emmanuel Engel; Karen Cohen
Journal:  Syst Rev       Date:  2015-06-12

8.  Sulforaphane protects rabbit corneas against oxidative stress injury in keratoconus through activation of the Nrf-2/HO-1 antioxidant pathway.

Authors:  Ruixing Liu; Xiaoming Yan
Journal:  Int J Mol Med       Date:  2018-08-10       Impact factor: 4.101

Review 9.  The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress.

Authors:  Ganesh Raghu; Michael Berk; Peter A Campochiaro; Hartmut Jaeschke; Giancarlo Marenzi; Luca Richeldi; Fu-Qiang Wen; Ferdinando Nicoletti; Peter M A Calverley
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.